      |
|
||||||||
|
Dr. Reinier Raymakers
Reinier Raymakers is active in clinical medicine, with a special interest in Multiple Myeloma and is member of the Dutch HOVON Myeloma group. In Multiple Myeloma idiotype, he was involved in DC vaccination, tested in a current protocol. He has shown that quantative measurement of minimal residual disease in multiple myeloma by ASO-PCR can be used to monitor vaccination results in addition to effects of reduced intensity allogeneic transplantation (HOVON-54). His basic research is focused on the role of ABC transporters in normal and leukemic stem cells. Some of these transporters are studied for their role in drug resistance; their role in stem cells is not yet elucidated. He is also interested in leukemia where functional defects were found in ABCB1. |
||||||||
|
Recent key publications Raaijmakers MH, Grouw EP, Heuver LH, Reijden BA, Jansen JH, Scheffer G, Scheper RJ, Witte de TJ, Raymakers RA. Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia. Clin Cancer Res. 2005 mar 15; 11(6):2436-2444
Raaijmakers MH, Grouw EP, Heuver LH, Reijden BA, Jansen JH, Scheffer G, Scheper RJ, Witte de TJ, Raymakers RA. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res. 2005 Dec; 29(12):1455-1458 Span LFR, Vierwinden G, Pennings AH, Boezeman JBM, Raymakers RAP, Witte de T. Programmed cell death is an intrinsic feature of MDS progenitors, predominantly found in the cluster-forming cells Experimental Hematology 33 (2005) 435-442 |
||||||||
